These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 9628247)
1. Automated and manual assays for urinary crosslinks of collagen: which assay to use? Seibel MJ; Woitge HW; Farahmand I; Oberwittler H; Ziegler R Exp Clin Endocrinol Diabetes; 1998; 106(2):143-8. PubMed ID: 9628247 [TBL] [Abstract][Full Text] [Related]
2. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. Robins SP; Woitge H; Hesley R; Ju J; Seyedin S; Seibel MJ J Bone Miner Res; 1994 Oct; 9(10):1643-9. PubMed ID: 7817812 [TBL] [Abstract][Full Text] [Related]
3. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. Seibel MJ; Woitge H; Scheidt-Nave C; Leidig-Bruckner G; Duncan A; Nicol P; Ziegler R; Robins SP J Bone Miner Res; 1994 Sep; 9(9):1433-40. PubMed ID: 7817828 [TBL] [Abstract][Full Text] [Related]
4. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats. DeLaurier A; Jackson B; Pfeiffer D; Ingham K; Horton MA; Price JS Res Vet Sci; 2004 Aug; 77(1):29-39. PubMed ID: 15120950 [TBL] [Abstract][Full Text] [Related]
5. [Urinary excretion of free and total deoxypyridinoline during secondary hyperparathyroidism in the elderly. Comparison of chromatographic (HPLC) and immunoenzymatic (Pyrilinks-D) methods]. Meddah B; Brazier M; Kamel S; Maamer M; Samson L; Desmet G; Sebert JL Ann Biol Clin (Paris); 1996; 54(10-11):353-8. PubMed ID: 9092303 [TBL] [Abstract][Full Text] [Related]
6. Effects of age, menopause and osteoporosis on free, peptide-bound and total pyridinium crosslink excretion. Del Campo MT; González-Casaus ML; Aguado P; Bernad M; Carrera F; Martínez ME Osteoporos Int; 1999; 9(5):449-54. PubMed ID: 10550465 [TBL] [Abstract][Full Text] [Related]
7. Analytical and clinical evaluation of the Bio-Rad HPLC kit for measurement of type I collagen cross links. Srivastava AK; Libanati C; Oberrauch W; Leenings J; Greenwald M; Baylink DJ J Bone Miner Metab; 2003; 21(3):134-44. PubMed ID: 12720047 [TBL] [Abstract][Full Text] [Related]
8. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. Woitge HW; Pecherstorfer M; Li Y; Keck AV; Horn E; Ziegler R; Seibel MJ J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528 [TBL] [Abstract][Full Text] [Related]
9. Markers of bone resorption--measurement in serum, plasma or urine? Huber F; Traber L; Roth HJ; Heckel V; Schmidt-Gayk H Clin Lab; 2003; 49(5-6):203-7. PubMed ID: 15285175 [TBL] [Abstract][Full Text] [Related]
10. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. Garnero P; Gineyts E; Arbault P; Christiansen C; Delmas PD J Bone Miner Res; 1995 Apr; 10(4):641-9. PubMed ID: 7610936 [TBL] [Abstract][Full Text] [Related]
11. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177 [TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy. Kitatani K; Nakatsuka K; Naka H; Miki T; Morii H; Nishizawa Y J Bone Miner Metab; 2003; 21(4):217-24. PubMed ID: 12811626 [TBL] [Abstract][Full Text] [Related]
13. The renal clearance of free and peptide-bound deoxypyridinoline: response to pamidronate treatment of Paget's disease. Naylor KE; Jackson B; Eastell R J Bone Miner Res; 2003 Apr; 18(4):658-61. PubMed ID: 12674326 [TBL] [Abstract][Full Text] [Related]
14. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links. Randall AG; Kent GN; Garcia-Webb P; Bhagat CI; Pearce DJ; Gutteridge DH; Prince RL; Stewart G; Stuckey B; Will RK; Retallack RW; Price RI; Ward L J Bone Miner Res; 1996 Aug; 11(8):1176-84. PubMed ID: 8854254 [TBL] [Abstract][Full Text] [Related]
15. Validation of a high-performance liquid chromatographic assay for lysylpyridinoline in urine: a potential biomarker of bone resorption. Casserly UM; O'Rorke A; Power MJ; Fottrell PF Anal Biochem; 1996 Nov; 242(2):255-60. PubMed ID: 8937570 [TBL] [Abstract][Full Text] [Related]
16. Multiple molecular forms of pyridinolines cross-links excreted in human urine evaluated by chromatographic and immunoassay methods. Kamel S; Brazier M; Neri V; Picard C; Samson L; Desmet G; Sebert JL J Bone Miner Res; 1995 Sep; 10(9):1385-92. PubMed ID: 7502711 [TBL] [Abstract][Full Text] [Related]
17. Effect of pamidronate on excretion of pyridinium crosslinks of collagen after total hip arthroplasty. Wilkinson JM; Jackson B; Eastell R Calcif Tissue Int; 2003 Oct; 73(4):326-31. PubMed ID: 12874697 [TBL] [Abstract][Full Text] [Related]
18. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. Garnero P; Gineyts E; Riou JP; Delmas PD J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361 [TBL] [Abstract][Full Text] [Related]
19. Standardization of marker assays--pyridinoline/deoxypyridinoline. Kent GN Scand J Clin Lab Invest Suppl; 1997; 227():73-9. PubMed ID: 9127470 [TBL] [Abstract][Full Text] [Related]
20. Free deoxypyridinoline in urine and serum--results in children and adolescents. Rauch F; Middelmann B; Rosmalen F; Seibel MJ; Schönau E Exp Clin Endocrinol Diabetes; 1996; 104(5):396-9. PubMed ID: 8957276 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]